Moreover, GSIs were confirmed to have a therapeutic effect in T-cell acute lymphoblastic leukemia (T-ALL), where more than 50% of patients harbor NOTCH1 activating mutations [36]. This evidence concerns the gene NOTCH1 and acute lymphoblastic leukemia.